Evidence map›Paper›PMID 42318451›Full record

ArticleJournal of pathology informatics2026

An integrated AI pipeline for automated cytogenetic analysis of bone marrow karyograms in hematological malignancies: A Pix2Pix enhancement and deep learning detection approach.

Lamia Alsubaie, Sarah Alsobaie, Nawaf Alhammad, Luluh Aldhubayi, Yazeed Al-Shaikh

Abstract read
In one paragraph

Article in Journal of pathology informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lamia AlsubaieDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Sarah AlsobaieDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Nawaf AlhammadArtificial Intelligence Center for Advanced Studies, King Saud University, Riyadh, Saudi Arabia.
Luluh AldhubayiDepartment of Information Technology, College of Computer and Information Sciences, King Saud University, Riyadh, Saudi Arabia.
Yazeed Al-ShaikhDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Conventional cytogenetic analysis remains central to the diagnosis and risk stratification of hematological malignancies but is constrained by labor-intensive workflows, inter-observer variability, and sensitivity to image quality. Although artificial intelligence (AI) approaches have been proposed for individual analytical tasks, clinically integrated, end-to-end pipelines aligned with reporting standards remain limited. Methods: We developed and evaluated a clinically oriented, AI-assisted cytogenetic analysis pipeline integrating image enhancement, chromosome detection, numerical and targeted structural abnormality assessment, and standardized reporting. Image quality was enhanced using a Pix2Pix-based generative model, followed by chromosome localization with a YOLOv8 detector and structural classification using a Siamese ResNet-18 architecture. Outputs were translated into ISCN-formatted reports aligned with College of American Pathologists (CAP) requirements. The system was evaluated retrospectively on clinical bone marrow karyogram datasets, with performance assessed using image-level fidelity metrics, analytical performance, and system-level feasibility under expert oversight. Results: Image enhancement demonstrated high structural fidelity (mean SSIM >0.98). Within a gated, quality-controlled pipeline, chromosome detection achieved robust performance, and the structural classifier showed strong discriminative ability for the targeted abnormality t(9;22). At the case level, primary concordance with expert interpretation was 85.8%, increasing to 92.35% following adjudication of clinically acceptable reporting differences. Automated generation of CAP-aligned ISCN reports was achieved under predefined quality-control constraints with mandatory expert validation. Conclusions: This study presents a clinically grounded, proof-of-concept AI-assisted cytogenetic decision-support pipeline integrating enhancement, gated analysis, abnormality assessment, and structured reporting. While demonstrating encouraging system-level performance, the framework is intended as a decision-support tool and remains at the stage of controlled feasibility evaluation. Further prospective validation, expanded structural coverage, and deployment-level governance will be required before clinical implementation.

Indexed as

Artificial intelligenceChromosomal abnormalitiesCytogeneticsDeep learningGenerative adversarial networksHematological malignanciesImage enhancementKaryotype analysis

Identifiers

PMID42318451
PMCPMC13273851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.